Immediate Impact
9 from Science/Nature 56 standout
Citing Papers
Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy
2025 Standout
Atopic dermatitis
2025 Standout
Works of Howard Kallender being referenced
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis
2025
Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Howard Kallender | 63 | 51 | 370 | 197 | 170 | 34 | 908 | |
| Xuemei Jiang | 28 | 6 | 426 | 86 | 136 | 61 | 975 | |
| Srinivas Chava | 2 | 2 | 602 | 151 | 70 | 41 | 1.2k | |
| Shijie Zhang | 13 | 1 | 314 | 102 | 103 | 65 | 793 | |
| Yuwen Zhou | 5 | 2 | 206 | 385 | 181 | 52 | 816 | |
| Han Li | 5 | 4 | 306 | 191 | 175 | 89 | 982 | |
| Shengdi Wu | 13 | 4 | 336 | 118 | 103 | 42 | 1.1k | |
| Yezaz A. Ghouri | 3 | 429 | 186 | 119 | 30 | 1.1k | ||
| Andrew E. Greenstein | 9 | 42 | 491 | 173 | 137 | 37 | 1.1k | |
| Anoma Nellore | 4 | 10 | 268 | 283 | 98 | 38 | 1.1k | |
| Hideaki Miwa | 32 | 1 | 213 | 264 | 76 | 64 | 816 |
All Works
Login with ORCID to disown or claim papers
Loading papers...